Resumen

BOURLON, María T.  y  SOBREVILLA-MORENO, Nora. Maintenance immunotherapy in advanced urothelial cancer. Gac. mex. oncol. [online]. 2022, vol.21, n.3, pp.99-109.  Epub 03-Oct-2022. ISSN 2565-005X.  https://doi.org/10.24875/j.gamo.220000801.

Advanced urothelial carcinoma usually responds to platinum-based chemotherapy (CT), although overall survival (OS) and progression-free survival are typically short. Immunotherapy is a promising treatment strategy, but first-line benefits in platinum-eligible patients are limited, and its combination with first-line chemotherapy has not been shown to benefit OS. Maintenance with immunotherapy in patients with clinical benefit is a strategy that takes advantage of the immunogenic effects of CT, as well as its antitumor activity and safety. Avelumab is the only inhibitor approved for first-line maintenance in patients with locally advanced or metastatic urothelial carcinoma that has not progressed with platinum-based CT. International guidelines recommend first-line maintenance avelumab as the standard of care for locally advanced or metastatic urothelial carcinoma that has not progressed with first-line chemotherapy.

Palabras llave : Avelumab; Urothelial carcinoma; Immunotherapy; Maintenance; PD-L1.